普拉克索联合左旋多巴对帕金森病患者认知功能的影响

Effect of Pramipexole Combined with Levodopa on Cognitive Function in Patients with Parkinson's Disease

目的探讨普拉克索联合左旋多巴治疗帕金森病的临床疗效,以及对患者认知功能的影响。方法选取湖北省十堰市竹山县人民医院2018年5月至2020年12月收治的帕金森病患者80例,随机分为观察组与对照组,各40例。对照组患者予普拉克索治疗,观察组患者在对照组治疗基础上联用左旋多巴,两组患者均持续治疗持3个月。结果观察组的临床总有效率为85.00%,显著高于对照组的65.00%(P<0.05);两组患者治疗后的改良Webster症状评分均显著降低,且观察组显著低于对照组(P<0.05);两组患者治疗后的简易精神状态评价量表(MMSE)和蒙特利尔认知量表(MoCA)评分均显著升高,且观察组显著高于对照组(P<0.05);两组患者治疗后的血清各项指标[超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)、过氧化氢酶(CAT)]水平均明显升高,且观察组显著高于对照组(P<0.05);观察组患者治疗期间的不良反应发生率为5.00%,显著低于对照组的22.50%(P<0.05)。结论普拉克索联合左旋多巴治疗帕金森病的临床疗效良好,且有利于患者认知功能的恢复,可缓解机体的氧化应激反应,安全性较高。

Objective To investigate the clinical efficacy of pramipexole combined with levodopa in the treatment of Parkinson's disease,and its effect on cognitive function in patients.Methods A total of 80 patients with Parkinson's disease admitted to the Zhushan County People's Hospital from May 2018 to December 2020 were randomly divided into the observation group and the control group,with 40 cases in each group.The patients in the control group were treated with pramipexole,while the patients in the observation group were treated with levodopa on the basis of the control group.Both groups were treated for three months.Results The total clinical effective rate in the observation group was 85.00%,which was significantly higher than 65.00%in the control group(P<0.05).The modified Webster symptom score in both groups after treatment significantly reduced,and that in the observation group was significantly lower than that in the control group(P<0.05).The MMSE and MoCA scores in the two groups after treatment significantly increased,and those in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the levels of various serum indicators[superoxide dismutase(SOD),reduced glutathione(GSH),and catalase(CAT)]in the two groups significantly increased,and those in the observation group were significantly higher than those in the control group(P<0.05).The incidence of fever adverse reactions during treatment in the observation group was 5.00%,which was significantly lower than the 22.50%in the control group(P<0.05).Conclusion Pramipexole combined with levodopa has a good clinical efficacy and high safety in the treatment of Parkinson's disease,and it is beneficial to the recovery of patients'cognitive function,which can alleviate the body's oxidative stress response.